Trevena CEO to Present at the 2010 UBS Global Life Sciences Conference
KING OF PRUSSIA, Pa.--(BUSINESS WIRE)-- Trevena, Inc., the industry leader in discovery and development of biased GPCR ligands, announced today that it will participate in the 2010 UBS Global Life Sciences Conference in New York. Maxine Gowen, Ph.D., president and chief executive officer of Trevena, will make a presentation on Tuesday, September 21, 2010 at 7:30 a.m. EDT.
Trevena, Inc. is a clinical stage pharmaceutical company focused on discovering and developing the next generation of G-protein coupled receptor (GPCR) targeted medicines. Despite the past success of GPCR drugs, there is huge scope to enhance the therapeutic properties of these molecules through targeted signaling. Trevena designs "biased ligands" that activate only those biological pathways at the receptor associated with beneficial effects, allowing them to unlock new biology and avoid drug side effects. TRV120027 is the most advanced drug in Trevena's pipeline, and the first biased ligand to be tested in humans. Phase 1 clinical studies of the drug were successfully completed earlier this year. Trevena is working to develop TRV120027 for the treatment of acute decompensated heart failure. Trevena's pipeline also includes programs with potential in pain and inflammation. Founded in 2008, Trevena is based in King of Prussia, Pennsylvania and is a privately held company backed by leading investors including Alta Partners, Healthcare Ventures, NEA, Polaris and Yasuda Enterprise Development Company. For more information about the company, please visit www.trevenainc.com.
Source: Trevena, Inc.
Released September 16, 2010